DOCSLIB.ORG

A Possible Approach for Treating FSHD with Rnai Therapeutics 4 10 16 24

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Possible Approach for Treating FSHD with Rnai Therapeutics 4 10 16 24 A Publication of the Facioscapulohumeral Muscular Dystrophy Society SUMMER 2011 RESEARCH ISSUE FSH Watch 2011 CONNECTING THE COMMUNITY OF PATIENTS, FAMILIES, CLINICIANS AND INVESTIGATORS TRANSLATIONAL RESEArcH Journey toward developing a drug for FSHD Perspectives and updates from recently funded FSH Society grantees by DARKO BOSNAKOVSKI, D.V.M., Ph.D. University Goce Delcev Stip, Macedonia lthough FSHD is considered one Aof the most common inherited neuromuscular diseases, there is no Dr. Davide Gabellini with fellow researchers at the 2010 FSH Society FSHD research workshop specific therapeutic practice for it. So what can we do about it? First, we have TRANSLATIONAL RESEArcH to understand the mechanisms of the disease and to identify the crucial links in the chain of molecular reactions A possible approach for treating FSHD that underline FSHD. Furthermore, we have to develop a system to screen with RNAi therapeutics various therapeutic approaches, and in Perspectives and updates from FSH Society grantees the end to generate an animal model where clinical relevance of therapy by DANIEL PEREZ scientists: the Harper Lab at The Ohio State can be determined. When I joined the FSH Society University and Nationwide Children’s Hos- FSHD group lead by Dr. Michael Kyba with contributions by DAVIDE GABELLINI, Ph.D. pital in Columbus, Ohio, with a collabo- at University of Texas Southwestern six Division of Regenerative Medicine, San Raffaele rator in Modena, Italy; and the Gabellini years ago to develop a specific therapy Scientific Institute, Milan, Italy, and and Chamberlain labs in Milan, Italy, and for FSHD all of the above was considered Seattle, Washington, respectively. SCOTT Q. HARPER, Ph.D. to be a big enigma. We started working Center for Gene Therapy, The Research Institute at RNA interference is a natural cellular with DUX41, the gene within D4Z4, due Nationwide Children’s Hospital, Columbus, Ohio process that controls the levels at which to the similarity of its homeodomains certain genes are expressed. In this sense, it to those of the master myogenic genes wo exciting papers were recently pub- operates less like an on/off switch and more Pax3 and Pax72. We postulated that both Tlished on possible approaches for treat- like a molecular volume control knob. genes compete for the same target DNA ing FSHD using a disease gene silencing Over the last several years, many scientists sequences and with that the function of approach called RNA interference (RNAi). have been working to co-opt these natural myogenic cells is impaired. At that time The details emerged within one month gene-silencing strategies for therapeutic only a small portion of the scientific of each other in the journal Molecular purposes. Indeed, the main triggers of community, led by Alexandra Belayew Therapy. The two complementary stud- RNAi in the cell, called inhibitory RNAs or . continued on page 27 ies were performed by different teams of microRNAs, can be rationally designed in the lab to knock down disease genes. In the WHAt’s inside two molecular therapy studies, the research teams rationally engineered FRG1-targeted page page page page inhibitory RNAs and then delivered them 4 10 16 24 (-high) In Memory of Understanding the FSHD Society NIH BBRI Wellstone to muscles of dystrophic FRG1 mice Edward Schechter function of the DUX4 Grants recently MD CRC for FSHD using adeno-associated viral (AAV) vectors, gene in FSHD awarded accomplishments . continued on page 8 F rom T H E F SH Soc I E T Y P R ESIDENT & C E O Dear Friends, his issue of the FSH Watch reports great advances and Please consider participating in Board of Directors Tdedicated people making remarkable progress to- studies highlighted in this issue, Daniel P. Perez, President & CEO ward understanding and treating FSHD. We are proud including the natural history William R. Lewis Sr., M.D., of the work detailed in this issue, moving us closer to study and developing biomark- Chairman Howard Chabner, J.D., understanding and treating FSHD. The FSH Society has ers for FSHD. Vice-Chairman made excellent progress in bringing scientists into the The FSH Society’s research Carol A. Perez, M.Ed., field, allowing them to train, and in giving them oppor- portfolio seeks a good balance Secretary William Michael, C.P.A., tunities to develop ideas in FSHD. We hope you agree. between conservative and in- Treasurer In last year’s research issue we highlighted Society novative approaches in devel- E. Ann Biggs-Williams Robert H. Brown Jr., M.D./ seed-funded work by Drs. Lemmers et al. in their paper oping our knowledge of how Daniel Paul Perez D.Phil.* “A Unifying Genetic Model for Facioscapulohumeral FSHD works. We are constantly James A. Chin Sr. President & CEO JoAnn P. Forance Muscular Dystrophy,” Science, August 19, 2010, that put readjusting between following David J. Glass, M.D. forth a unified and long-sought explanation of the exact the “published paradigm” to William S. Herzberg Beth E. Johnston, M.B.A. biological workings of a disease that affects an esti- guide FSHD progress with that of setting out in new Louis M. Kunkel, Ph.D. mated one in 14,000 or 22,100 Americans and 490,000 innovative directions to improve our understanding C. Larry Laurello, P.E. William R. Lewis III, M.D. individuals worldwide. Subsequently the Society an- of the disease. Both attitudes are appropriate. In times Michelle H. Mackay, M.A. nounced that it helped to fund a second critical advance like these, when the research community struggles with Theodore L. Munsat, M.D.* Paul Schultz, M.D.* in determining the cause of FSHD in PLoS Genetics, developing a high-confidence therapeutic target, a bias Judith Seslowe, M.A. “Facioscapulohumeral Dystrophy: Incomplete Suppres- towards innovation is appropriate. Robert F. Smith, Esq. Christopher Stenmon, C.P.A. sion of a Retrotransposed Gene,” on October 28, 2010, A top priority as outlined by the international com- Scientific Advisory Board that shows that the disease is caused by the inefficient munity during the most recent Society research planning David E. Housman, Ph.D., suppression of a DUX4 gene that is normally expressed workshop is to independently verify and confirm the Chairman only in early development. DUX4 hypothesis as published in Science in 2010. And if Michael R. Altherr, Ph.D. Robert H. Brown Jr., M.D./ The FSH Society’s approach to solving FSHD is confirmed, move to understand normal DUX4 function, D.Phil. pragmatic. We are now studying the “FSHD causing and finally, move towards understanding the naturally Rune R. Frants, Ph.D. David J. Glass, M.D. targets” in our translational research phase to enable us occurring variability of DUX4 to allow scientists to Louis M. Kunkel, Ph.D. to initiate therapeutic clinical trials. In this issue, we manipulate the disease in our favor. Currently, the pub- William R. Lewis Sr., M.D. William R. Lewis III, M.D. highlight efforts in each of the areas supported by the lished paradigm is that DUX4 is necessary and sufficient Katherine D. Mathews, M.D. Society – mechanistic, translational, pre-clinical and to cause FSHD. However, if it turns out that DUX4 is Theodore L. Munsat, M.D.* George W. Padberg, M.D. clinical. The FSH Society continues to fund ground necessary but not sufficient or even not necessary to Paul Schultz, M.D.* breaking and early-stage efforts in research, translational cause FSHD, then the choices of a target and pathway Kathryn Wagner, M.D., Ph.D. research, small molecule screening and clinical efforts. are markedly different. It is one thing to eliminate a pro- General Counsel Morgan Downey, J.D. As you read about the projects we’ve recently funded tein that you are not supposed to have at all in muscle Washington, DC and the updates from scientists all over the world, please and another to modulate a protein that has a resolution * Board Member Emeritus remember that great things are happening, and they near the noise floor of detection and may be expressed are only made possible by your financial donations and at different thresholds in individuals with FSHD and FSH Watch willingness to actively participate in research efforts. without FSHD. SUMMER 2011 It is our editorial policy to report on developments regarding FacioScapuloHumeral Muscular Dystrophy (FSHD), but not to endorse any of the drugs or treatments discussed. We urge you to consult with your own physician about the procedures mentioned. Nancy Van Zant Executive Director [email protected] The FSH Watch is published by the FSH Society and distributed by mail to its members and supporters. All material is copyrighted and may not be reproduced without written permission. To be placed on the mailing list or to submit an article, please write to: Daniel Paul Perez Research Programs Nancy Van Zant, Executive Director [email protected] FSH Society, Inc. Patient Resource c/o BBRI R353, 64 Grove Street, Watertown, MA 02472 USA Peer-to-Peer Team [email protected] Call or email the Society office to make contact Articles may be edited for space and clarity. Every effort has been made to ensure accuracy in the newsletter. If you wish to correct an error, please write to the above address. FSH Society, Inc. 64 Grove Street Look for us on the internet at: www.fshsociety.org Watertown, MA 02472 USA 617-658-7878, -7877 Editors: Daniel Paul Perez and Nancy Van Zant. 617-658-7879 Fax Editorial assistance: Howard Chabner, Carol Perez, Susan Perez and Charles Perez. Graphic design & editorial assistance: Leslie Anne Feagley www.fshsociety.org 2 • FSH Watch • SUMMER 2011 Two papers on possible approaches for treating FSHD using established for other dystrophies.
Load more

Recommended publications
  • DUX4, a Zygotic Genome Activator, Is Involved in Oncogenesis and Genetic Diseases Anna Karpukhina, Yegor Vassetzky
    DUX4, a Zygotic Genome Activator, Is Involved in Oncogenesis and Genetic Diseases Anna Karpukhina, Yegor Vassetzky To cite this version: Anna Karpukhina, Yegor Vassetzky. DUX4, a Zygotic Genome Activator, Is Involved in Onco- genesis and Genetic Diseases. Ontogenez / Russian Journal of Developmental Biology, MAIK Nauka/Interperiodica, 2020, 51 (3), pp.176-182. 10.1134/S1062360420030078. hal-02988675 HAL Id: hal-02988675 https://hal.archives-ouvertes.fr/hal-02988675 Submitted on 17 Nov 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. ISSN 1062-3604, Russian Journal of Developmental Biology, 2020, Vol. 51, No. 3, pp. 176–182. © Pleiades Publishing, Inc., 2020. Published in Russian in Ontogenez, 2020, Vol. 51, No. 3, pp. 210–217. REVIEWS DUX4, a Zygotic Genome Activator, Is Involved in Oncogenesis and Genetic Diseases Anna Karpukhinaa, b, c, d and Yegor Vassetzkya, b, * aCNRS UMR9018, Université Paris-Sud Paris-Saclay, Institut Gustave Roussy, Villejuif, F-94805 France bKoltzov Institute of Developmental Biology of the Russian Academy of Sciences,
    [Show full text]
  • Neuromuscular Disease Journal Article on IRC 2019
    Available online at www.sciencedirect.com Neuromuscular Disorders 29 (2019) 811–817 www.elsevier.com/locate/nmd Research conference report 26th Annual Facioscapulohumeral Dystrophy International Research Congress Marseille, France, 19–20 June 2019 a b, ∗ c June Kinoshita , Frédérique Magdinier , George W. Padberg a FSHD Society, 450 Bedford Street, Lexington, MA, USA b Aix Marseille Univ, INSERM, MMG, Marseille Medical Genetics, Marseille, France c Radboud UMC, Nijmegen, The Netherlands Received 2 August 2019 1. Introduction In the welcome session, Mark Stone, CEO of the FSHD Society, summarized the international patient advocacy group Research in Facioscapulohumeral Muscular Dystrophy meeting that was held on the previous day (June 18), which (FSHD) has reached the stage where we are seeing the gathered representatives of patients associations from six first drug trials aiming at reduction of its pathological gene European countries as well as Brazil, China, Israel, Japan, product DUX4. Driven by this development and by increased and the United States. international collaboration on translational research and trial preparedness, the FSHD Society has decided to hold its 2. Plenary and keynote lectures annual International Research Conference (IRC) alternating between the USA and in Europe, beginning this year with the The meeting opened with a plenary session aimed at 26th IRC held in Marseille, France. The meeting occurred on presenting the condition from the point of view of affected 19–20 June, 2019, at the Palais du Pharo, a historical palace individuals. A 10-min video gave an intimate look into the built in the second half of the 19th century by Napoleon III life of Pierre Laurian.
    [Show full text]
  • 2021 IRC Abstract Book
    ABSTRACT BOOK THANK YOU TO OUR SPONSORS S = session; P = poster; author in bold = presenting author Page | 2 SPEAKER PRESENTATIONS DAY 1 – THURSDAY, JUNE 24, 2021 . Discovery Research S1.100 Transient DUX4 expression provokes long-lasting cellular and molecular muscle alterations Darko Bosnakovski, Ahmed Shams, Madison Douglas, Natalie Xu, Christian Palumbo, David Oyler, Elizabeth Ener, Daniel Chi, Erik Toso, Michael Kyba S1.101 Identification of the first endogenous inhibitor of DUX4 in FSHD muscular dystrophy Paola Ghezzi, Valeria Runfola, Maria Pannese, Claudia Caronni, Roberto Giambruno, Annapaola Andolfo, Davide Gabellini S1.102 Use of snRNA-seq to characterize the skeletal muscle microenvironment during pathogenesis in FSHD Anugraha Raman, Anthony Accorsi, Michelle Mellion, Bobby Riehle, Lucienne Ronco, L. Alejandro Rojas, Christopher Moxham . Genetics & Epigenetics S2.200 Identification of a druggable epigenetic target required for DUX4 expression and DUX4-mediated toxicity in FSHD muscular dystrophy Emanuele Mocciaro, Roberto Giambruno, Stefano Micheloni, Cristina Consonni, Maria Pannese, Valeria Runfola, Giulia Ferri, Davide Gabellini S2.201 Accessing D4Z4 (epi)genetics with long-read sequencing Quentin Gouil, Ayush Semwal, Frédérique Magdinier, Marnie Blewitt . Pathology & Disease Mechanisms S3.300 System biology approach links muscle weakening to alteration of the contractile apparatus in FSHD Camille Laberthonnière, Megane Delourme, Raphael Chevalier, Elva-Maria Novoa-del-Toro, Emmanuelle Salort Campana, Shahram Attarian,
    [Show full text]
  • FSHD Region Gene 1 (FRG1) Is Crucial for Angiogenesis Linking FRG1 to Facioscapulohumeral Muscular Dystrophy-Associated Vasculopathy
    University of Massachusetts Medical School eScholarship@UMMS Peter Jones Lab Publications Cell and Developmental Biology Laboratories 2009-05-01 FSHD region gene 1 (FRG1) is crucial for angiogenesis linking FRG1 to facioscapulohumeral muscular dystrophy-associated vasculopathy Ryan Wuebbles University of Illinois at Urbana-Champaign Et al. Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/peterjones Part of the Cell Biology Commons, Developmental Biology Commons, Molecular Biology Commons, Molecular Genetics Commons, Musculoskeletal Diseases Commons, and the Nervous System Diseases Commons Repository Citation Wuebbles R, Hanel ML, Jones PL. (2009). FSHD region gene 1 (FRG1) is crucial for angiogenesis linking FRG1 to facioscapulohumeral muscular dystrophy-associated vasculopathy. Peter Jones Lab Publications. https://doi.org/10.1242/dmm.002261. Retrieved from https://escholarship.umassmed.edu/ peterjones/11 Creative Commons License This work is licensed under a Creative Commons Attribution 3.0 License. This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Peter Jones Lab Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. Disease Models & Mechanisms 2, 267-274 (2009) doi:10.1242/dmm.002261 RESEARCH ARTICLE FSHD region gene 1 (FRG1) is crucial for angiogenesis linking FRG1 to facioscapulohumeral muscular dystrophy-associated vasculopathy Ryan D. Wuebbles1,*, Meredith L. Hanel1,* and Peter L. Jones1,‡ SUMMARY The genetic lesion that is diagnostic for facioscapulohumeral muscular dystrophy (FSHD) results in an epigenetic misregulation of gene expression, which ultimately leads to the disease pathology. FRG1 (FSHD region gene 1) is a leading candidate for a gene whose misexpression might lead to FSHD.
    [Show full text]
  • Gene Expression During Normal and FSHD Myogenesis Tsumagari Et Al
    Gene expression during normal and FSHD myogenesis Tsumagari et al. Tsumagari et al. BMC Medical Genomics 2011, 4:67 http://www.biomedcentral.com/1755-8794/4/67 (27 September 2011) Tsumagari et al. BMC Medical Genomics 2011, 4:67 http://www.biomedcentral.com/1755-8794/4/67 RESEARCHARTICLE Open Access Gene expression during normal and FSHD myogenesis Koji Tsumagari1, Shao-Chi Chang1, Michelle Lacey2,3, Carl Baribault2,3, Sridar V Chittur4, Janet Sowden5, Rabi Tawil5, Gregory E Crawford6 and Melanie Ehrlich1,3* Abstract Background: Facioscapulohumeral muscular dystrophy (FSHD) is a dominant disease linked to contraction of an array of tandem 3.3-kb repeats (D4Z4) at 4q35. Within each repeat unit is a gene, DUX4, that can encode a protein containing two homeodomains. A DUX4 transcript derived from the last repeat unit in a contracted array is associated with pathogenesis but it is unclear how. Methods: Using exon-based microarrays, the expression profiles of myogenic precursor cells were determined. Both undifferentiated myoblasts and myoblasts differentiated to myotubes derived from FSHD patients and controls were studied after immunocytochemical verification of the quality of the cultures. To further our understanding of FSHD and normal myogenesis, the expression profiles obtained were compared to those of 19 non-muscle cell types analyzed by identical methods. Results: Many of the ~17,000 examined genes were differentially expressed (> 2-fold, p < 0.01) in control myoblasts or myotubes vs. non-muscle cells (2185 and 3006, respectively) or in FSHD vs. control myoblasts or myotubes (295 and 797, respectively). Surprisingly, despite the morphologically normal differentiation of FSHD myoblasts to myotubes, most of the disease-related dysregulation was seen as dampening of normal myogenesis- specific expression changes, including in genes for muscle structure, mitochondrial function, stress responses, and signal transduction.
    [Show full text]
  • The Role of Long Non-Coding Rnas in the Pathogenesis of Hereditary Diseases Peter Sparber1*, Alexandra Filatova1, Mira Khantemirova2,3 and Mikhail Skoblov1,4
    Sparber et al. BMC Medical Genomics 2019, 12(Suppl 2):42 https://doi.org/10.1186/s12920-019-0487-6 REVIEW Open Access The role of long non-coding RNAs in the pathogenesis of hereditary diseases Peter Sparber1*, Alexandra Filatova1, Mira Khantemirova2,3 and Mikhail Skoblov1,4 From 11th International Multiconference “Bioinformatics of Genome Regulation and Structure\Systems Biology” - BGRS\SB- 2018 Novosibirsk, Russia. 20-25 August 2018 Abstract Background: Thousands of long non-coding RNA (lncRNA) genes are annotated in the human genome. Recent studies showed the key role of lncRNAs in a variety of fundamental cellular processes. Dysregulation of lncRNAs can drive tumorigenesis and they are now considered to be a promising therapeutic target in cancer. However, how lncRNAs contribute to the development of hereditary diseases in human is still mostly unknown. Results: This review is focused on hereditary diseases in the pathogenesis of which long non-coding RNAs play an important role. Conclusions: Fundamental research in the field of molecular genetics of lncRNA is necessary for a more complete understanding of their significance. Future research will help translate this knowledge into clinical practice which will not only lead to an increase in the diagnostic rate but also in the future can help with the development of etiotropic treatments for hereditary diseases. Keywords: Long non-coding RNA, lncRNA, Hereditary disease, Gene regulation, Medical genetics Introduction The second group includes rRNAs and long non-coding In 1958, Francis Crick proposed the central dogma of mo- RNAs (lncRNAs), which to date are very poorly function- lecular biology in which he explained the flow of genetic ally annotated.
    [Show full text]
  • SNF2 Chromatin Remodeler-Family Proteins FRG1 and -2 Are Required for RNA-Directed DNA Methylation
    SNF2 chromatin remodeler-family proteins FRG1 and -2 are required for RNA-directed DNA methylation Martin Grotha, Hume Strouda,1, Suhua Fenga,b,c, Maxim V. C. Greenberga,2, Ajay A. Vashishtd, James A. Wohlschlegeld, Steven E. Jacobsena,b,c,3, and Israel Ausine,3 aDepartment of Molecular, Cell, and Developmental Biology, bEli & Edythe Broad Center of Regenerative Medicine & Stem Cell Research, dDepartment of Biological Chemistry, David Geffen School of Medicine, cHoward Hughes Medical Institute, University of California, Los Angeles, CA 90095; and eBasic Forestry and Biotechnology Center, Fujian Agriculture and Forestry University, Fujian, Fuzhou 350002, China Contributed by Steven E. Jacobsen, October 29, 2014 (sent for review August 2, 2014) DNA methylation in Arabidopsis thaliana is maintained by at least four (6, 7). Recruitment of Pol V is mediated by methyl-CG–binding different enzymes: DNA METHYLTRANSFERASE1 (MET1), CHROMO- noncatalytic Su(var)3-9 histone methyltransferase homologs METHYLASE3 (CMT3), DOMAINS REARRANGED METHYLTRANSFER- SUVH2 and SUVH9, and a putative chromatin remodeling ASE2 (DRM2), and CHROMOMETHYLASE2 (CMT2). However, DNA complex called the DRD1-DMS3-RDM1 complex (8, 9). In ad- methylation is established exclusively by the enzyme DRM2, which dition to SUVH2 and SUVH9, SUVR2 from the same family of acts in the RNA-directed DNA methylation (RdDM) pathway. Some SET-domain proteins was also identified as an RdDM factor by RdDM components belong to gene families and have partially redun- a systematic analysis of DNA methylation defects in mutants of dant functions, such as the endoribonucleases DICER-LIKE 2, 3,and4, Su(var)3-9 homologs (10). However, the precise molecular function and INVOLVED IN DE NOVO2 (IDN2) interactors IDN2-LIKE 1 and 2.
    [Show full text]
  • CIC-DUX4 Induces Small Round Cell Sarcomas Distinct from Ewing Sarcoma
    Author Manuscript Published OnlineFirst on April 12, 2017; DOI: 10.1158/0008-5472.CAN-16-3351 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. CIC-DUX4 induces small round cell sarcomas distinct from Ewing sarcoma Toyoki Yoshimoto 1, 2, Miwa Tanaka1, Mizuki Homme1, Yukari Yamazaki1, Yutaka Takazawa3, Cristina R Antonescu4, and Takuro Nakamura1 1Division of Carcinogenesis, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan. 2Department of Pathology, Toranomon Hospital, Tokyo Japan. 3Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo Japan. 4Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York. Running title: Mouse model for CIC-DUX4 sarcoma Keywords: CIC-DUX4, sarcoma model, Ccnd2, Muc5ac, biomarker The abbreviations used are: CDS, CIC-DUX4 sarcoma; ES, Ewing sarcoma; eMC, embryonic mesenchymal cell; SS, synovial sarcoma; RS, rhabdomyosarcoma; EMCS, extraskeletal myxoid chondrosarcoma; GSEA, gene set enrichment analysis; ECM, extracellular matrix; MSC, mesenchymal stem cell. Grant Support: The study was supported by Grants-in-Aid for Scientific Research from Japan Society for the Promotion of Science (no. 26250029 to T. Nakamura), and Cancer Center Support grants (P50 CA140146 and P30-CA008747 to C. R. Antonescu) from the U.S. National Institute of Health. Corresponding Author: Takuro Nakamura, Division of Carcinogenesis, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan. Phone: 81-3-3570-0462; E-mail: [email protected] T. Yoshimoto and M. Tanaka contributed equally to this article. The manuscript includes 3,775 words, five figures and two tables.
    [Show full text]
  • The DNA Sequence and Comparative Analysis of Human Chromosome 20
    articles The DNA sequence and comparative analysis of human chromosome 20 P. Deloukas, L. H. Matthews, J. Ashurst, J. Burton, J. G. R. Gilbert, M. Jones, G. Stavrides, J. P. Almeida, A. K. Babbage, C. L. Bagguley, J. Bailey, K. F. Barlow, K. N. Bates, L. M. Beard, D. M. Beare, O. P. Beasley, C. P. Bird, S. E. Blakey, A. M. Bridgeman, A. J. Brown, D. Buck, W. Burrill, A. P. Butler, C. Carder, N. P. Carter, J. C. Chapman, M. Clamp, G. Clark, L. N. Clark, S. Y. Clark, C. M. Clee, S. Clegg, V. E. Cobley, R. E. Collier, R. Connor, N. R. Corby, A. Coulson, G. J. Coville, R. Deadman, P. Dhami, M. Dunn, A. G. Ellington, J. A. Frankland, A. Fraser, L. French, P. Garner, D. V. Grafham, C. Grif®ths, M. N. D. Grif®ths, R. Gwilliam, R. E. Hall, S. Hammond, J. L. Harley, P. D. Heath, S. Ho, J. L. Holden, P. J. Howden, E. Huckle, A. R. Hunt, S. E. Hunt, K. Jekosch, C. M. Johnson, D. Johnson, M. P. Kay, A. M. Kimberley, A. King, A. Knights, G. K. Laird, S. Lawlor, M. H. Lehvaslaiho, M. Leversha, C. Lloyd, D. M. Lloyd, J. D. Lovell, V. L. Marsh, S. L. Martin, L. J. McConnachie, K. McLay, A. A. McMurray, S. Milne, D. Mistry, M. J. F. Moore, J. C. Mullikin, T. Nickerson, K. Oliver, A. Parker, R. Patel, T. A. V. Pearce, A. I. Peck, B. J. C. T. Phillimore, S. R. Prathalingam, R. W. Plumb, H. Ramsay, C. M.
    [Show full text]
  • The DUX4 Homeodomains Mediate Inhibition of Myogenesis and Are Functionally Exchangeable with the Pax7 Homeodomain Darko Bosnakovski1,2, Erik A
    © 2017. Published by The Company of Biologists Ltd | Journal of Cell Science (2017) 130, 3685-3697 doi:10.1242/jcs.205427 RESEARCH ARTICLE The DUX4 homeodomains mediate inhibition of myogenesis and are functionally exchangeable with the Pax7 homeodomain Darko Bosnakovski1,2, Erik A. Toso2, Lynn M. Hartweck2, Alessandro Magli3, Heather A. Lee2, Eliza R. Thompson2, Abhijit Dandapat2, Rita C. R. Perlingeiro3 and Michael Kyba2,* ABSTRACT downstream target genes, compared with controls (Celegato et al., Facioscapulohumeral muscular dystrophy (FSHD) is caused by 2006; Krom et al., 2012; Rahimov et al., 2012; Tassin et al., 2012; inappropriate expression of the double homeodomain protein DUX4. Tsumagari et al., 2011; Winokur et al., 2003a,b). In our previous work, DUX4 DUX4 has bimodal effects, inhibiting myogenic differentiation and we demonstrated that ,whenexpressedatlowlevelsinC2C12 blocking MyoD at low levels of expression, and killing myoblasts at myoblasts, recapitulates aspects of this FSHD myoblast phenotype, high levels. Pax3 and Pax7, which contain related homeodomains, namely that it sensitizes cells to oxidative stress and severely reduces MyoD antagonize the cell death phenotype of DUX4 in C2C12 cells, mRNA and protein levels (Bosnakovski et al., 2008b). High DUX4 suggesting some type of competitive interaction. Here, we show that levels of expression caused cell death (Bosnakovski et al., the effects of DUX4 on differentiation and MyoD expression require the 2008b). In addition to these effects, myoblasts expressing low levels of DUX4 homeodomains but do not require the C-terminal activation domain of had diminished differentiation potential, presumably caused DUX4. We tested the set of equally related homeodomain proteins by dysregulation of myogenic regulatory factors (MRFs), including (Pax6, Pitx2c, OTX1, Rax, Hesx1, MIXL1 and Tbx1) and found MyoD (Bosnakovski et al., 2008b).
    [Show full text]
  • Fulcrum WMS DUX4 FSHD Poster
    Targeting DUX4 Expression, the Root Cause of FSHD: Identification of a Drug Target and Development Candidate Owen B. Wallace, Anthony Accorsi, Richard Barnes, Angela Cacace, Diego Cadavid, Aaron Chang, David Eyerman, Robert Gould, Steven Kazmirski, Joseph Maglio, Michelle Mellion, Peter Rahl, Alan Robertson, Alejandro Rojas, Lucienne Ronco, Ning Shen, Lorin A. Thompson and Erin Valentine Fulcrum Therapeutics. 26 Landsdowne Street, Cambridge, Massachusetts, USA. Abstract 4. Losmapimod reduces DUX4 activation and its downstream consequences • FSHD is caused by the loss of repression at the D4Z4 locus leading to aberrant DUX4 expression A. 150 in skeletal muscle, activation of its early embryo transcriptional program and muscle fiber death. 125 100 • While some progress toward understanding the signals driving DUX4 expression has been made, 75 the factors and pathways involved in the transcriptional activation of this gene remain largely 50 unknown. 25 (% of nuclei in MHC mask) MHC in nuclei of (% % of DMSO% of control 0 • Using optimized myotube culture conditions, we identified p38 MAPK as a key regulator of DUX4 0.001 0.01 0.1 1 expression. [Losmapimod] µM • We observed that treatment with the p38α/β inhibitor losmapimod results in reduction of DUX4 B. C. expression, activity and cell death in FSHD patient-derived myotubes with minimal impact on WT FSHD myogenesis. 125 MBD3L2 mRNA 100 • RNA-seq studies revealed that only a small number of genes were differentially expressed after Active Caspase-3 treatment with losmapimod, ~90% of these are targets of DUX4. 75 50 • Fulcrum Therapeutics has selected losmapimod, a specific p38α/β inhibitor, for clinical 25 development in FSHD.
    [Show full text]
  • Human Proteins That Interact with RNA/DNA Hybrids
    Downloaded from genome.cshlp.org on October 4, 2021 - Published by Cold Spring Harbor Laboratory Press Resource Human proteins that interact with RNA/DNA hybrids Isabel X. Wang,1,2 Christopher Grunseich,3 Jennifer Fox,1,2 Joshua Burdick,1,2 Zhengwei Zhu,2,4 Niema Ravazian,1 Markus Hafner,5 and Vivian G. Cheung1,2,4 1Howard Hughes Medical Institute, Chevy Chase, Maryland 20815, USA; 2Life Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109, USA; 3Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland 20892, USA; 4Department of Pediatrics, University of Michigan, Ann Arbor, Michigan 48109, USA; 5Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland 20892, USA RNA/DNA hybrids form when RNA hybridizes with its template DNA generating a three-stranded structure known as the R-loop. Knowledge of how they form and resolve, as well as their functional roles, is limited. Here, by pull-down assays followed by mass spectrometry, we identified 803 proteins that bind to RNA/DNA hybrids. Because these proteins were identified using in vitro assays, we confirmed that they bind to R-loops in vivo. They include proteins that are involved in a variety of functions, including most steps of RNA processing. The proteins are enriched for K homology (KH) and helicase domains. Among them, more than 300 proteins preferred binding to hybrids than double-stranded DNA. These proteins serve as starting points for mechanistic studies to elucidate what RNA/DNA hybrids regulate and how they are regulated.
    [Show full text]